(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.03%.
Aligos Therapeutics's earnings in 2026 is -$24,193,000.On average, 7 Wall Street analysts forecast ALGS's earnings for 2026 to be -$44,294,798, with the lowest ALGS earnings forecast at -$52,757,242, and the highest ALGS earnings forecast at -$32,226,099. On average, 6 Wall Street analysts forecast ALGS's earnings for 2027 to be -$38,516,623, with the lowest ALGS earnings forecast at -$48,512,407, and the highest ALGS earnings forecast at -$25,144,154.
In 2028, ALGS is forecast to generate -$6,038,062 in earnings, with the lowest earnings forecast at -$38,870,566 and the highest earnings forecast at $40,152,680.